The Emerging Role of gut Microbiota in Immunotherapy
DOI:
https://doi.org/10.61173/y9xm8s24Keywords:
Gut microbiota, immunotherapy, microenvironmentAbstract
The gastrointestinal tract contains a diverse and dynamic population of microorganisms called the gut microbiota, which is essential for immune system regulation. Recent studies have highlighted that gut microbiota has a major influence on the effectiveness of cancer immunotherapy, particularly immune checkpoint antagonists. This review explores the mechanisms of specific gut microbiota, such as Bifidobacterium and Lactobacillus, to enhance innate and adaptive immune responses, including activation of dendritic cells, polarization of macrophages, and stimulation of CD8+ T cells. In addition, this review discusses therapeutic strategies aimed at manipulating the gut microbiota to enhance the effects of immunotherapy, including fecal microbiota transplantation (FMT), probiotics, and engineered microbiota. Although these approaches have promising potential, the challenges still remain with the variability of patients and microbiota manipulation. This review emphasizes how crucial it is to combine immunotherapy and the gut microbial community to create more individualized, effective cancer treatments, which will eventually improve patient outcomes and advance the area of cancer treatment.
References
[1] Mager LF, Burkhard R, Pett N, et al. 2020. Microbiomederived inosine modulates response to checkpoint inhibitor immunotherapy. Science. 2020; 369(6510): 1481-1489.
[2] Gopalakrishnan V, Spencer CN, Nezi L, et al. 2017. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2017; 35: 97-103.
[3] Sivan A, Corrales L, Hubert N, et al. 2015. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science. 2017; 350 (6264):1084-1089.
[4] Lin L, Rayman P, Pavicic PG, et al. 2018. Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-γ. Cancer Immunol Immunother. 2018; 68(3):395-405.
[5] Peng W, Li YH, Yang G, et al. 2022. Oral administration of Lactobacillus delbrueckii enhances intestinal immunity through inducing dendritic cell activation in suckling piglets. The Royal Society of Chemistry. 2022; 13: 2570-2580.
[6] Li QX, Li Y, Wang YF. 2021. Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12. Oncolmmunology. 2021; 10(1).
[7] Calvo A, Pastor Y, Rosas-Val P, et al. 2024. Unveiling the immunomodulatory effect of the novel probiotic Akkermansia muciniphila and its protective effect in vitro. Microbiological Research. 2024; 283: 127677.
[8] Han Y, Ling Q, Wu L, et al. 2022. Akkermansia muciniphila inhibits nonalcoholic steatohepatitis by orchestrating TLR2- activated γδT17 cell and macrophage polarization. Gut Microbes. 2022; 15(1).
[9] Deng HM, Li ZC, Tan YF, et al. 2016. A novel strain of Bacteroides fragilis enhances
[10] Mowat C, Dhatt J, Bhatti I, et al. 2023. Short chain fatty acids prime colorectal cancer cells to activate antitumor immunity. Frontiers in Immunology. 2023; 14.
[11] Siavoshian S, Blottière HM, Bentouimou N, et al. 1996. Butyrate enhances major histocompatibility complex class I, HLA-DR and ICAM-1 antigen expression on differentiated human intestinal epithelial cells. European Journal of Clinical Investigation. 1996; 26(9):803-810.
[12] Botta C, Spyridopoulou K, Bertolino M, et al. 2022. Lactiplantibacillus plantarum inhibits colon cancer cell proliferation as function of its butyrogenic capability. Biomedicine & Pharmacotherapy. 2022; 149:112755. Dean&Francis
[13] Chang SC, Shen MH, Liu CY, et al. 2020. A gut butyrateproducing bacterium Butyricicoccus pullicaecorum regulates shortchain fatty acid transporter and receptor to reduce the progression of 1,2dimethylhydrazineassociated colorectal cancer. Oncology Letters. 2020;20(6): 1792-1082.
[14] Chang CC, Kao WY, Liu CY, et al. 2022. Butyrate supplementation regulates expression of chromosome segregation 1‑like protein to reverse the genetic distortion caused by p53 mutations in colorectal cancer. International Journal of Oncology. 2022; 60(6): 1791-2423.
[15] Heo G, Lee Y, Im E. 2021. Interplay between the Gut Microbiota and Inflammatory Mediators in the Development of Colorectal Cancer. Cancer. 2021; 13(4): 734.
[16] James D. 2003. Inhibition of Histone Deacetylase Activity by Butyrate. The Journal of Nutrition. 2003;133 (7): 24855- 24935.
[17] Hu M, Alashkar AB, Santner-Nanan B, et al. 2022 Short- Chain Fatty Acids Augment Differentiation and Function of Human Induced Regulatory T Cells. Int. J. Mol. Sci. 2022; 23(10): 5740.
[18] Jaroonwitchawan T, Arimochi H, Sasski Y, et al. 2023. Stimulation of the farnesoid X receptor promotes M2 macrophage polarization. Frontiers in Immunology. 2023; 14.
[19] Biagioli M, Carino A, Cipriani S, et al. 2017. The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis. The Journal of Immunology. 2017; 199(2): 718-733.
[20] Centuori SM, Martinez JD. 2014. Differential Regulation of EGFR–MAPK Signaling by Deoxycholic Acid (DCA) and Ursodeoxycholic Acid (UDCA) in Colon Cancer. Digestive Diseases and Sciences. 2014; 59: 2367-2380.
[21] Baunwall SMD, Lee MM, Eriksen MK, et al. 2020. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis. eClinicalMedicine. 2020; 29: 100642.
[22] Baruch EN, Youngster I, Ben-betzalel G, et al. 2020. Fecal microbiota transplant promotes response in immunotherapyrefractory melanoma patients. Science. 2020; 371: 602-609.
[23] Scagnolari C, Scheri GC, Selvaggi C, et al. 2016. Probiotics Differently Affect Gut-Associated Lymphoid Tissue Indolamine- 2,3-Dioxygenase mRNA and Cerebrospinal Fluid Neopterin Levels in Antiretroviral-Treated HIV-1 Infected Patients: A Pilot Study. International Journal of Molecular Sciences. 2016; 17(10):1639.
[24] Chauhan VP, Jain RK. 2013. Strategies for advancing cancer nanomedicine. Nature materials. 2013; 12: 958-962.
[25] Zhang ZW, Wang H, Tan T, et al. 2018. Rational Design of Nanoparticles with Deep Tumor Penetration for Effective Treatment of Tumor Metastasis. Advanced Functional Materials. 2018; 28(40): 1801840.
[26] Li JY, Ding YF, Wang ZY, et al. 2024. TAM-preferential nanoparticles intracellularly self-assembled for enhanced macrophage repolarization and cancer immunotherapy. Nanotoday. 2024; 54: 102104.
[27] Qian Y, Qiao S, Dai YF, et al. 2017. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor- Associated Macrophages. ACS Nano. 2017;11(9): 9536–9549.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
